May 8 |
Apollomics Announces Private Placement Financing and Addition to Board of Directors
|
Apr 25 |
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
|
Apr 10 |
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
Apr 2 |
Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
|
Mar 28 |
Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript
|
Mar 28 |
Apollomics GAAP EPS of -$2.32
|
Mar 28 |
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
|
Mar 26 |
Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
|
Mar 4 |
Apollomics Names Matthew Plunkett as Chief Financial Officer
|
Mar 4 |
Apollomics appoints CFO
|